Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
Regulatory

Quantum Biopharma lawsuit featured in W5 series

By The Northwire Desk — AI Analysis Nov 26, 2025 · 18:50 QNTM · 16.23 Quantum Biopharma Ltd
QNTM · Price

Executive Summary

  • Quantum Biopharma Ltd. is the subject of a three-part investigative series on CTV News' flagship program W5, focusing on the company's $700 million U.S. lawsuit alleging stock market manipulation (specifically stock spoofing) against major Canadian banks CIBC and RBC.
  • The series highlights the company's lead drug candidate, Lucid-MS, for multiple sclerosis, and CEO Zeeshan Saeed’s statement regarding the harmful effects of spoofing on retail investors and the company's mission to bring the drug to market.
  • The release outlines the company's broader portfolio, including its 19.86% stake in Unbuzzd Wellness Inc. and associated royalty agreements, as well as its strategic investment subsidiary.

Key Details

  • Lawsuit Details: Quantum Biopharma is pursuing a $700 million (U.S.) lawsuit against CIBC and RBC.
  • Allegation: The lawsuit alleges "stock spoofing," an illegal market manipulation tactic in both Canada and the United States.
  • Media Coverage: CTV News' W5 investigative reporter Jon Woodward is airing a three-part series titled "Was a Canadian company's multiple sclerosis research nearly derailed by 'market manipulation'?"
  • Lead Drug Candidate: Lucid-MS is a patented new chemical entity designed to prevent and reverse myelin degradation (the underlying mechanism of multiple sclerosis) in preclinical models.
  • Unbuzzd Wellness Inc. Stake: Quantum Biopharma retains 19.86% ownership of Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.) as of September 30, 2025.
  • Royalty Agreement: The agreement with Unbuzzd Wellness includes a 7% royalty on sales of the "unbuzzd" product until Quantum Biopharma receives $250 million in total payments. After this threshold, the royalty drops to 3% in perpetuity.
  • Pharmaceutical Rights: Quantum Biopharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
  • Strategic Investments: The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Notable Quotes

  • Zeeshan Saeed, CEO: "We thank W5 for their important investigation into the illegal, but little known, practice of stock spoofing and some of its harmful effects on retail investors. Our goal has always been to bring Lucid-MS -- a potentially game-changing drug that in animal studies has been shown to stop and even reverse the degradation of nerve cells (a hallmark of multiple sclerosis) giving back mobility and control to the body unlike any drug today for the benefit of millions of people around the world who courageously live with this progressive and debilitating disease. By shining a light on our experience with alleged stock market manipulation, we hope to prevent other companies, their shareholders and their beneficiaries, from experiencing what we have been through."
Read the original news release →

More from Quantum Biopharma Ltd

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other